For the love of God, people, the financial terms of the Amgen deal have been the subject of an SEC Confidential Treatment Order since August 2016. That means that there must be a clause in the agreement with Amgen that prevents ADXS from disclosing a milestone payment. It will not show up in the next quarterly report if there is a milestone for the first dosing. The lack of a PR is completely meaningless, and tells us nothing.